Neoadjuvant and adjuvant therapy in relation to surgery for colorectal liver metastases

References

• Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer 1996;77:1254–62.
   PubMed Web of Science ®Google Scholar
• Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:818–25.
   PubMed Web of Science ®Google Scholar
• Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F−18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004;240:438–47.
   PubMed Web of Science ®Google Scholar
• Adam R, Bhangui P, Poston G, Mirza D, Nuzzo G, Barroso E, Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg 2010;252:774–87.
   PubMed Web of Science ®Google Scholar
• Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371:1007–16.
   PubMed Web of Science ®Google Scholar
• Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005;23:2038–48.
   PubMed Web of Science ®Google Scholar
• Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240:644–57.
   PubMed Web of Science ®Google Scholar
• de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Schulick RD, Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 2009;250:440–8.
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005;241:715–22.
   PubMed Web of Science ®Google Scholar
• Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J, Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006;24:4976–82.
   PubMed Web of Science ®Google Scholar
• Lorenz M, Muller HH, Schramm H, Gassel HJ, Rau HG, Ridwelski K, Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases. Ann Surg 1998;228:756–62.
   PubMed Web of Science ®Google Scholar
• Kemeny N, Huang Y, Cohen AM, Shi W, Conti JA, Brennan MF, Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999;341:2039–48.
   PubMed Web of Science ®Google Scholar
• Kemeny MM, Adak S, Gray B, Macdonald JS, Smith T, Lipsitz S, Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol 2002;20:1499–505.
   PubMed Web of Science ®Google Scholar
• Langer B, Bleiberg H, Labianca R, Shepherd L, Nitti D, Marsoni S, Fluorouracil (FU) plus leucovorin (I-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial [abstract 592]. Proc Am Soc Clin Oncol 2002;21:149a.
   Google Scholar
• Mitry E, Fields A, Bleiberg H, Labianca R, Portier G, Tu D, Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials. J Clin Oncol 2008;26:4906–11.
   PubMed Web of Science ®Google Scholar
• Ychou M, Hohenberger W, Thezenas S, Navarro M, Maurel J, Bokemeyer C, A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 2009;20:1964–70.
   PubMed Web of Science ®Google Scholar
• Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010;11:38–47.
   PubMed Web of Science ®Google Scholar
• Wong R, Saffery C, Barbachano Y, Saffery C, Valle J, Hickish T, BOXER: a multicentre phase II trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with liver-only metastases from colorectal cancer unsuitable for upfront resection. Ann Oncol 2011; Epub ahead of print.
   Google Scholar
• Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G, Rougier P, Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009;20:985–92.
   PubMed Web of Science ®Google Scholar
• de Gramont A, Bosset JF, Milan C, Rougier P, Bouché O, Etienne PL, Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808–15.
   PubMed Web of Science ®Google Scholar
• de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938–47.
   PubMed Web of Science ®Google Scholar
• Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041–7.
   PubMed Web of Science ®Google Scholar
• Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:1670–6.
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–42.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408–17.
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663–71.
   PubMed Web of Science ®Google Scholar
• Rivoire M, De Cian F, Meeus P, Négrier S, Sebban H, Kaemmerlen P. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer 2002;95:2283–92.
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999;10:663–9.
   PubMed Web of Science ®Google Scholar
• Meric F, Patt YZ, Curley SA, Chase J, Roh MS, Vauthey JN, Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol 2000;7:490–5.
   PubMed Web of Science ®Google Scholar
• Goéré D, Deshaies I, de Baere T, Boige V, Malka D, Dumont F, Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg 2010;251:686–91.
   PubMed Web of Science ®Google Scholar
• Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005;16:1311–19.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011–19.
   PubMed Web of Science ®Google Scholar
• Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011;377:2103–14.
   PubMed Web of Science ®Google Scholar
• Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697–705.
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Yi J, Ince W, Novotny WF, Rosen O. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 2009;14:22–8.
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013–19.
   PubMed Web of Science ®Google Scholar
• Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L, Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009;101:1033–8.
   PubMed Web of Science ®Google Scholar
• Masi G, Cupini S, Marcucci L, Cerri E, Loupakis F, Allegrini G, Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol 2006;13:58–65.
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–16.
   PubMed Web of Science ®Google Scholar
• Adam R, Wicherts DA, de Haas RJ, Ciacio O, Lévi F, Paule B, Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 2009;27:1829–35.
   PubMed Web of Science ®Google Scholar
• Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S, Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 2009;249:420–5.
   PubMed Web of Science ®Google Scholar
• Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27:3677–83.
   PubMed Web of Science ®Google Scholar
• Alberts SR, Roh MS, Mahoney MR, O'Connell MJ, Nagorney DM, Wagman L, Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a north central cancer treatment group (NCCTG)/national surgical adjuvant breast and bowel project (NSABP) phase II intergroup trial, N9945/CI-66. J Clin Oncol 2010;28:853–8.
   Web of Science ®Google Scholar
• Allen PJ, Kemeny N, Jarnagin W, DeMatteo R, Blumgart L, Fong Y, Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 2003;7:109–15.
   PubMed Web of Science ®Google Scholar
• Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004;240:1052–61.
   PubMed Web of Science ®Google Scholar
• Chun YS, Vauthey JN, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M, Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009;302:2338–44.
   PubMed Web of Science ®Google Scholar
• Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V, Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 2007;18:299–304.
   PubMed Web of Science ®Google Scholar
• Adam R, Wicherts DA, de Haas RJ, Aloia T, Lévi F, Paule B, Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol 2008;26:1635–41.
   PubMed Web of Science ®Google Scholar
• Blazer DG 3rd, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008;26:5344–51.
   PubMed Web of Science ®Google Scholar
• Wein A, Riedel C, Bruckl W, Merkel S, Ott R, Hanke B, Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-h infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer. Oncology 2003;64:131–8.
   PubMed Web of Science ®Google Scholar
• Taieb J, Artru P, Paye F, Louvet C, Perez N, André T, Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. J Clin Oncol 2005;23:502–9.
   PubMed Web of Science ®Google Scholar
• Benoist S, Brouquet A, Penna C, Julié C, El Hajjam M, Chagnon S, Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006;24:3939–45.
   PubMed Web of Science ®Google Scholar
• Elias D, Goere D, Boige V, Kohneh-Sharhi N, Malka D, Tomasic G, Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol 2007;14:3188–94.
   PubMed Web of Science ®Google Scholar
• Auer RC, White RR, Kemeny NE, Schwartz LH, Shia J, Blumgart LH, Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 2010;116:1502–9.
   PubMed Web of Science ®Google Scholar
• van Vledder MG, de Jong MC, Pawlik TM, Schulick RD, Diaz LA, Choti MA. Disappearing colorectal liver metastases after chemotherapy: should we be concerned? J Gastrointest Surg 2010;14:1691–700.
   PubMed Web of Science ®Google Scholar
• Zalinski S, Abdalla EK, Mahvash A, Vauthey JN. A marking technique for intraoperative localization of small liver metastases before systemic chemotherapy. Ann Surg Oncol 2009;16:1208–11.
   PubMed Web of Science ®Google Scholar
• Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006;243:1–7.
   PubMed Web of Science ®Google Scholar
• Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006;24:2065–72.
   PubMed Web of Science ®Google Scholar
• Parikh AA, Gentner B, Wu TT, Curley SA, Ellis LM, Vauthey JN. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg 2003;7:1082–8.
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 2007;11:860–8.
   PubMed Web of Science ®Google Scholar
• Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004;15:460–6.
   PubMed Web of Science ®Google Scholar
• Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005;200:845–53.
   PubMed Web of Science ®Google Scholar
• Brouquet A, Benoist S, Julie C, Penna C, Beauchet A, Rougier P, Risk factors for chemotherapy-associated liver injuries: a multivariate analysis of a group of 146 patients with colorectal metastases. Surgery 2009;145:362–71.
   PubMed Web of Science ®Google Scholar
• Kooby DA, Fong Y, Suriawinata A, Gonen M, Allen PJ, Klimstra DS, Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 2003;7:1034–44.
   PubMed Web of Science ®Google Scholar
• Nakano H, Oussoultzoglou E, Rosso E, Casnedi S, Chenard-Neu MP, Dufour P, Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 2008;24.118–24.
   PubMed Web of Science ®Google Scholar
• Soubrane O, Brouquet A, Zalinski S, Terris B, Brézault C, Mallet V, Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Ann Surg 2010;251:454–60.
   PubMed Web of Science ®Google Scholar
• Aloia T, Sebagh M, Plasse M, Karam V, Lévi F, Giacchetti S, Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006;24:4983–90.
   PubMed Web of Science ®Google Scholar
• Sørensen P, Edal AL, Madsen EL, Fenger C, Poulsen MR, Petersen OF. Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluorouracil. Cancer 1995;75:2592–6.
   PubMed Web of Science ®Google Scholar
• Welsh FK, Tilney HS, Tekkis PP, John TG, Rees M. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer 2007;96:1037–42.
   PubMed Web of Science ®Google Scholar
• Pessaux P, Marzano E, Casnedi S, Bachellier P, Jaeck D, Chenard MP. Histological and immediate postoperative outcome after preoperative cetuximab: case-matched control study. World J Surg 2010;34:2765–72.
   PubMed Web of Science ®Google Scholar
• Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008;26:1830–5.
   PubMed Web of Science ®Google Scholar
• D'Angelica M, Kornprat P, Gonen M, Chung KY, Jarnagin WR, DeMatteo RP, Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol 2007;14:759–65.
   PubMed Web of Science ®Google Scholar
• Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 2008;26:5254–60.
   PubMed Web of Science ®Google Scholar
• Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB, Eng C, Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007;110:2761–7.
   PubMed Web of Science ®Google Scholar